References

• 2012Interrater reliability: the kappa statistic19,799 cited
• 2017Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13600 cited
• 2008Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma229 cited
• 2015From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients196 cited
• 2017Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration196 cited
• 2015Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study189 cited
• 2016Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014186 cited
• 2017Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review121 cited
• 2014New FDA Breakthrough-Drug Category — Implications for Patients119 cited
• 2005Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures109 cited
• 2015Approvals of drugs with uncertain benefit–risk profiles in Europe93 cited
• 2017Accelerated Approval and Expensive Drugs — A Challenging Combination81 cited
• 2013Development Times, Clinical Testing, Postmarket Follow-up, and Safety Risks for the New Drugs Approved by the US Food and Drug Administration